|
|
News Breaks | | | | September 24, 2012 | | 07:48 EDT |  | WPI | Watson Pharmaceuticals price target raised to $100 from $90 at Canaccord
Canaccord recommends Watson into year end based on expected updates on debt pricing, Actavis closing, and initial 2013 guidance. The firm also sees potential upside in 2014 for Gx Conerta and Lidoderm. Shares are Buy rated. | |
|
News For WPI From The Last 14 Days Check below for free stories on WPI the last two weeks. |
|
|
| There are no results for WPI |
|
|
|
|
|
|
